PMVP ▼ -12.3% - PMV Pharmaceuticals, Inc. $PMVP - PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial PMV Pharmaceuticals fell 12.3% today despite announcing updated interim data from its Phase 2 pivotal trial of rezatapopt as a monotherapy for ovarian cancer. The market's negative reaction to the announcement suggests investors found the trial results disappointing relative to expectations, though the headline characterizes the data as promising. 31-AUG-2026 04:01 PM ET